[18F]fluoroethylnormemantine

[18F]FNM (also known as [18F]fluoroethylnormemantine or [18F]FENM) is a fluorine-18-labeled small-molecule radiotracer derived from memantine, developed for positron emission tomography (PET) imaging of the N-methyl-D-aspartate receptor (NMDAR). It acts as an uncompetitive antagonist that selectively binds to the phencyclidine (PCP) site within the open and active state of the NMDAR channel pore. Developed by ReST Therapeutics in collaboration with academic institutions including the Toulouse Neuroimaging Center (ToNIC), INSERM, and the University of Toulouse, [18F]FNM is utilized as a diagnostic imaging agent to track NMDAR activation and distribution in preclinical and clinical models of neurological and neuropsychiatric disorders, such as brain injury, Alzheimer's disease, and Tourette syndrome.

Other names

[18F]-FENM[18F]-FNM[18F]-fluoroethylnormemantine[18F]FENM[18F]FNM